Seth J. Baum, MD In 2013 Dr. Tom Frieden, Director of the CDC, judiciously proclaimed that “even one preventable death is one too many.” Just three years later we are mired in debates concerning cost effectiveness of innovative medicines. We argue about not only the price of drugs, but also the monetized value of a…

Read More

by Seth J. Baum MD Recently, there have been several articles discussing the development, efficacy, cost and long-term impact of novel cholesterol lowering drugs – called PCSK9 inhibitors – new drugs that show the capacity to greatly reduce the levels of LDL, or “bad”, cholesterol in an individual’s bloodstream. Insurance providers have pushed back aggressively…

Read More

by Seth J. Baum MD PCSK9 inhibitors are the most significant advance in the management of elevated cholesterol in the last 3 decades. These injectable medications are indisputably revolutionary: They provide intensive and predictable reduction of LDL cholesterol in even our most difficult-to-treat patients. So, you would think that insurance providers would embrace them. Not…

Read More

Important research recently published in the American Heart Association’s journals illustrates that the cardiovascular disease burden and treatment patterns among patients with familial hypercholesterolemia (FH) in the US remain poorly described. The study consisted of a cross-sectional analysis of 1295 adults with heterozygous FH enrolled in the FH Foundation’s CASCADE-FH Registry from 11 US lipid…

Read More

by Seth J. Baum, MD A recent article by Caroline Humer and Ransdell Pierson for Reuters reported on the unexpectedly paltry number of prescriptions for PCSK9 inhibitors, the revolutionary cholesterol lowering drugs that were FDA approved in the summer of 2015. Insurance providers had viewed these costly medications as a potentially grave threat to their…

Read More